Coming off a year that saw a record number of new drug approvals, significant scientific breakthroughs and a year - end tax reform package that both significantly lowers corporate taxes and provides the long - awaited tax repatriation holiday, it's not surprising that biotech investors, executives and
advisers were in a good mood as they gathered in San Francisco this year for the J.P. Morgan Healthcare Conference.